United Therapeutics CEO Martine Rothblatt Executes Planned Stock Sales and Option Exercise on Same Day

Chief Executive Officer Exercises 9,500 Stock Options Under Rule 10b5-1 Plan

Martine A. Rothblatt, serving as both Chairperson and CEO of United Therapeutics, exercised 9,500 stock options on July 28, 2026, at a strike price of $135.42 per share. The option exercise was part of a coordinated series of transactions executed on the same day and represents a significant equity activity for the company's top executive. The disclosure indicates that these options were eligible for exercise, with an expiration date of March 15, 2027, meaning the CEO exercised them relatively close to their termination date.

According to the filing, the option exercise was conducted pursuant to a pre-arranged trading plan adopted by Rothblatt on November 7, 2025. This plan, which falls under Rule 10b5-1(c), represents an affirmative defense mechanism that allows insiders to establish predetermined trading schedules to avoid accusations of trading on material nonpublic information. The plan is designed to operate under strict parameters, with the exercise of the 9,500 options on July 28, 2026, representing only a portion of the total permitted activity under the arrangement.

Coordinated Share Sales Execute Across Multiple Price Points on Single Trading Day

Following the option exercise, Rothblatt sold 10,057 shares in 10 separate transactions, all executed on July 28, 2026. The sales were not conducted at a uniform price; instead, they occurred across a range of trading prices throughout the day. The first sale involved 1,367 shares at a weighted average price of $523.1544 per share, and subsequent sales progressed at incrementally higher prices. The final sale of 40 shares executed at a weighted average price of $532.4895 per share, indicating that the share price moved upward during the execution window.

Each individual sale transaction was itself executed in multiple trades, with the reported prices representing weighted averages of those constituent trades. For example, the 1,367-share sale occurred at prices ranging from $522.59 to $523.58, while the largest single-day sale of 1,473 shares ranged from $525.73 to $526.71. This multi-step execution approach is typical of large insider sales designed to minimize market impact and achieve optimal pricing across a trading session. The filing notes that Rothblatt undertakes to provide the SEC, the issuer, or security holders with full information regarding the number of shares and specific prices at which each transaction was effected upon request.

Pre-Arranged Trading Plan Parameters and Duration

The disclosure reveals important details about the structure and timeline of Rothblatt's 10b5-1 trading plan. The plan was formally adopted on November 7, 2025, approximately eight months before the July 28, 2026, transaction date. According to the filing, the plan will continue operating until the earlier of two events: the exercise of a total of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026. This means the plan has a hard deadline at year-end 2026, regardless of how many additional options may remain unexercised.

The pre-arranged nature of the plan is significant from a regulatory perspective, as it demonstrates that the CEO's trading activity on July 28, 2026, was not reactive to any specific market condition or corporate development occurring on that date. Instead, the transactions were scheduled weeks or months in advance, reducing concerns that insider trading might have occurred based on material nonpublic information. The filing explicitly confirms that the July 28, 2026, transaction was made pursuant to this contract and written plan, satisfying the affirmative defense conditions outlined in Rule 10b5-1(c).

Post-Transaction Beneficial Ownership Through Family Trust Structures

Following the reported transactions on July 28, 2026, Rothblatt's beneficial ownership of United Therapeutics common stock was held primarily through family trust structures. The filing indicates that 324,443 shares were held indirectly through a trust described as one in which the reporting person shares investment power and for which the reporting person and immediate family members are beneficiaries. An additional 249,108 shares were held in a trust where the reporting person's spouse is the sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Beyond the shares acquired and disposed of on July 28, 2026, Rothblatt held additional shares through other family trust arrangements. The filing discloses 45,596 shares in a trust where the reporting person's spouse shares investment power, and 8,902 shares in a trust where the reporting person serves as sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Rothblatt also held 40,513 shares directly and 166 shares indirectly through a spouse-related arrangement. The aggregate beneficial ownership position following the transactions reflected a substantial equity stake in United Therapeutics held across multiple legal structures.

Stock Option Holdings and Future Exercise Capacity

In addition to common stock ownership, Rothblatt held derivative securities in the form of stock options following the July 28, 2026, transactions. The filing indicates that 255,910 stock options were held indirectly through a family trust structure in which the reporting person shares investment power and the reporting person and immediate family members are beneficiaries. These options have a strike price of $135.42 per share, the same price at which the 9,500 options were exercised on July 28, 2026, and expire on March 15, 2027.

The availability of 255,910 additional options at the same strike price suggests that Rothblatt retains substantial capacity to acquire additional shares through future exercises under the pre-arranged trading plan. Given that the plan permits exercise of up to 1,734,410 total options and that approximately 9,500 had been exercised by July 28, 2026, the plan appears designed to facilitate a systematic program of option exercises and share sales over the remaining life of the arrangement. The March 15, 2027, expiration date creates a window for all remaining option exercises, as options expiring on that date cannot be exercised after that time.

Direct and Indirect Beneficial Ownership Composition

The filing reveals that Rothblatt's beneficial ownership of United Therapeutics is structured across both direct and indirect holdings, with the indirect holdings predominating. Direct ownership consisted of 40,513 common shares held in the reporting person's own name. The spouse held 166 shares indirectly through a spouse-related arrangement. The remainder of the beneficial ownership position, comprising more than 615,000 shares, was held indirectly through various family trust structures with differing legal characteristics and beneficiary compositions.

This trust-based ownership structure is not uncommon among senior executives and controlling shareholders, as it can offer various estate planning and liability protection benefits. The specific nature of each trust relationship is disclosed in the filing, allowing investors and regulators to understand the character of each holding and the degree of control or influence the CEO retains over assets held in each structure. The diversity of trust arrangements suggests that Rothblatt's family has implemented a comprehensive wealth management strategy spanning multiple generations and legal entities.

Ownership Distribution Across Multiple Trust Vehicles

The disclosure demonstrates that Rothblatt's beneficial ownership is distributed across four distinct family trust vehicles, each with different characteristics regarding trustee roles, beneficiary status, and investment decision-making authority. The primary trust holding 324,443 shares is one in which the CEO shares investment power with the reporting person and immediate family members as beneficiaries. A second trust holds 249,108 shares where the reporting person's spouse serves as sole trustee and sole beneficiary or as co-trustee and settlor with power to revoke, indicating a structure that may have been established by the spouse or jointly.

A third trust arrangement holds 45,596 shares in which the spouse shares investment power with the reporting person, and immediate family members are beneficiaries. A fourth trust holds 8,902 shares where the reporting person serves as sole trustee and sole beneficiary or as co-trustee and settlor with power to revoke. This final structure may represent a personal or spousal trust created by the CEO. The aggregate amount held across all four trust vehicles totals 627,649 shares, underscoring the significance of trust-based holdings in the CEO's overall ownership position at United Therapeutics.

Transaction Execution Methodology and Market Context

The manner in which Rothblatt executed the stock sales on July 28, 2026, reflects a deliberate approach to managing a substantial equity disposition. Rather than selling all 10,057 shares in a single transaction, the CEO executed 10 separate sales ranging from 40 to 1,473 shares each. This phased execution approach typically reflects an intent to minimize market disruption and potentially achieve better average pricing across a trading session. The fact that each individual sale itself consisted of multiple constituent trades further suggests an algorithmic or broker-assisted execution designed to achieve price efficiency.

The progression of weighted average prices across the 10 sales, beginning at $523.1544 and ending at $532.4895, indicates that the share price appreciated during the execution window on July 28, 2026. This upward price movement during the execution period suggests that the phased approach allowed Rothblatt to capture some of the intraday price appreciation. The filing undertakes to provide full details of the specific number of shares and prices for each constituent trade within each of the 10 reported sales, ensuring transparency regarding the precise execution of these significant transactions.

Regulatory Compliance and Insider Trading Safeguards

The use of a Rule 10b5-1 trading plan by Rothblatt demonstrates adherence to regulatory best practices designed to prevent insider trading allegations. By adopting a pre-arranged, non-discretionary trading schedule in advance of possessing any material nonpublic information that might be in effect on the trading dates, the CEO creates an affirmative defense against potential accusations of trading based on confidential information. The plan's adoption on November 7, 2025, approximately eight months before the July 28, 2026, transaction, provides substantial temporal distance between the plan adoption and the execution date.

The disclosure document itself notes that the CEO checked the box indicating that transactions were made pursuant to a contract, instruction, or written plan satisfying Rule 10b5-1(c) conditions. The filing also explicitly states in the explanation of responses that the exercise of stock options and sale of resulting shares was pursuant to the pre-arranged 10b5-1 trading plan. This transparency regarding the regulatory framework governing the transactions provides investors and regulators with confidence that the trading activity was conducted in compliance with insider trading prohibitions and did not occur based on material nonpublic information.

Beneficial Ownership Analysis and Shareholder Concentration

Following the July 28, 2026, transactions, Rothblatt's beneficial ownership position in United Therapeutics reflected a significant equity stake in the company. The aggregate beneficial ownership across all direct and indirect holdings totaled 619,642 shares of common stock, plus an additional 255,910 stock options with a strike price of $135.42. The composition of this ownership—with more than 99 percent held indirectly through family trust structures rather than directly—is typical of long-tenured executives or founder-related shareholders who have established comprehensive estate planning arrangements.

The size of this ownership position, relative to the company's total outstanding shares, would position Rothblatt as a substantial shareholder, though the filing does not disclose the overall percentage of the company's equity represented by these holdings. Investors analyzing United Therapeutics' ownership structure and governance may consider the implications of the CEO maintaining such a significant beneficial ownership position, including potential alignment of executive and shareholder interests as well as potential implications for corporate control and decision-making authority within the company.